NVDA vs PLXS

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.

PLXS exhibits exceptional financial health with a perfect Piotroski F-Score of 9/9 and a very low Debt/Equity ratio of 0.13. However, the stock is significantly overvalued, trading at $222.88, which is well above both its Graham Number ($89.63) and its growth-based Intrinsic Value ($167.76). While the earnings track record is stellar with consistent beats over 25 quarters, bearish insider sentiment and a weak technical trend suggest a potential price correction. The disconnect between the 'Buy' analyst recommendation and a target price ($200.80) that is lower than the current market price further supports a cautious stance.